Use of Olanzapine for Elderly Patients With Psychotic Disorders: A Review

References

• Kaplan HI, Sadock BJ: Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 8th edn. Williams & Wilkins; 1998
   Google Scholar
• Zagas EM, Grossberg GT: The treatment of psychosis in late life. J Clin Psychiatry 1998; 59(Suppl 1):5–10
   Google Scholar
• Thorpe L: The treatment of psychotic disorders in late life. CanJ Psychiatry 1997; 42\(Suppl 1):19S–27S
   Google Scholar
• Pearlson G, Rabins P: The late onset of psychosis: Possible risk factors. Psychiatr Chit North Am 1998; 11:15–32
   Google Scholar
• Devanand DP, Levy SR: Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neu rol 1995; 8(Suppl 1):518–527
   Google Scholar
• Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA: Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756–765
   PubMed Web of Science ®Google Scholar
• Saltz BL, Kane JM, Woerner MG, Lieberman LA, Alvir JM, Blank K, Kahaner K, Foley C: Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 1989; 25: 52–56
   Google Scholar
• Avorn J, Monane M, Everitt DE, Beers MH, Fields D: Clin-ical assessments of extrapyramidal signs in nursing home pa-tients given antipsychotic medication. Arch Intern Med 1994; 154:1113–1117
   Google Scholar
• Madhusoodanan S, Brenner R, Cohen CL: Role of atypical antipsychotics in the treatment of psychosis and agitation as-sociated with dementia. CNS Drugs 1999; 12(2):135–150
   Google Scholar
• Physicians' Desk Reference, 55th ed., Montvale, NJ: Medical Economics Company; 2001
   Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine.Neuropsychopharma-cology 1996; 14:87–96
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PFM, Gommeren W, Luyten WH, VanGompel P, Lesage AS, Deloore K, Leysen JE: Risperi-done compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996; 124:57–73
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238–246
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet J-M, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Milian MJ: Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and re-lease in mesolimbic, mesocortical, and nigrostriatal pathways. J Pharmacol Exp Ther 1995; 275:899–913
   Google Scholar
• Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW: Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, al-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996; 124:87–94
   PubMed Web of Science ®Google Scholar
• Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, Wei H: Olanzapine for psychotic conditions in the elderly. Psychiatr Ann 2000; 30(3):191–196
   Google Scholar
• Zyprexa (Olanzapine): Product Monograph. Eli Lilly & Com-pany; Oct. 1996
   Google Scholar
• Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaf-fective and schizophreniform disorders: Results of an inter-national collaborative trial. Am .1 Psychiatry 1997; 154:457–465
   PubMed Web of Science ®Google Scholar
• Kuntz AJ, Reams SG, Sanger TM, Beasley CM: Olanzapine in the treatment of elderly patients with schizophrenia and re-lated psychotic disorders. Paper presented at the 9th Biennial Winter Workshop on Schizophrenia; Feb. 7–13,1998; Davos, Switzerland
   Google Scholar
• Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799–812
   Web of Science ®Google Scholar
• Montgomery SA, Asburg M: A new depression scale de-signed to be sensitive to change. Br J Psychiatry 1979; 134:382–389
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JWS: Drug-induced extrapyramidal dis-orders. Acta Psychiatr Scand 1970; 45(Suppl 212):11–19
   Google Scholar
• Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacol-ogy. (Publication ADM 76-338). Washington, DC: U.S. De-partment of Health, Education and Welfare; 1976
   Google Scholar
• Sajatovic M, Perez D, Brescan D, Ramirez LF: Olanzapine therapy in elderly patients with schizophrenia. Psychophar-macol Bull 1998; 34(4):819–823
   Web of Science ®Google Scholar
• Folstein MF, Folstein SE, Hugh PR: Mini Mental State. A prac-tical method for grading the cognitive state of patients by the clinician. .1 Psychiatric Res 1975; 12:189–198
   Google Scholar
• Madhusoodanan S, Brenner R, Suresh P, Concepcion NM, Florita CD, Menon G, Kaur A, Nunez G, Reddy H: Effi-cacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study. Ann Clin Psychia-try 2000; 12(1):11–18
   Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Ex-trapyramidal Symptoms Rating. Am J Neurol Sci 1980; 7:233
   Google Scholar
• Addington D, Addington J, Schissel BA: Calgary Depres-sion Scale for Schizophrenia: Depression rating scale for schizophrenics. Schizophr Res 1990; 3:247–251
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S. Suresh R Brenner R, Pillai R: Experience with the atypical antipsychotics-Risperidone and Olanzapine in the elderly. Ann Chit Psychiatry 1999; 11(3):113–118
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Bri J Psychiatry 1978; 133:429–435
   PubMed Web of Science ®Google Scholar
• Spearing MK, Post PM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatr Res 1997; 73:159–171
   PubMed Web of Science ®Google Scholar
• Hamilton M: Development of a rating scale for primary depressive illness. Bri J Soc Clin Psychol 1967; 6:278–296
   PubMed Web of Science ®Google Scholar
• Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic depressive cycle and changes caused by treatment. Pharmacopsychiatria 1980; 13:156–167
   Google Scholar
• Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD: A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psy-chopharmacol Bull 1995; 31:534
   Google Scholar
• Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's dis-ease: Phenomenology and treatment. J Clin Psychiatry 1987; 48(Suppl 5):9–15
   PubMed Web of Science ®Google Scholar
• Street J, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tolefson GD, Breier A: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomised, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychia-try 2000; 57(10):968–976
   Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gorbein J: The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308–2314
   PubMed Web of Science ®Google Scholar
• Clark WS, Street JS, Sanger TM, Feldman PD, Breier A: Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. Paper presented at the 14th annual meet-ing of the American Association for Geriatric Psychiatry; Feb. 23–26,2001; San Francisco, CA
   Google Scholar
• Solomons K, Geiger 0: Olanzapine use in the elderly: A ret-rospective analysis. Can J Psychiatry 2000; 45:151–155
   PubMed Web of Science ®Google Scholar
• Frenchman B, Dang JC, Prince T: Effects of risperidone, haloperidol, and olanzapine on behavioral symptoms in nurs-ing home patients. Paper presented at the 11th annual meeting of the American Association for Geriatric Psychiatry; March 8–12,1998; San Diego, CA
   Google Scholar
• Wolters EC, Jansen EN, Thynman-Qua HG, Bergmans PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47(4):1195–1196
   Google Scholar
• Aarsland D, Larsen JP, Lim NG, Tandberg E: Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999; 11(3):392–394
   PubMedGoogle Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ: Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6):789–794
   PubMed Web of Science ®Google Scholar
• Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, Campbell M, Perry R, Ince P: The UPDRS scale as a means of identifying extrapyramidal signs in patients suf-fering from dementia with Lewy bodies. Acta Neurol Scand 1997; 96:366–371
   PubMed Web of Science ®Google Scholar
• Rudolf J, Ghaemi M, Schmulling S: Deterioration of Parkin-sonian symptoms following treatment of dopaminergic hallu-cinosis with olanzapine. Eur Psychiatry 1999; 14(6):356–357
   Google Scholar
• Friedman JH, Goldstein S, Jacques C: Substituting clozap-ine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study. Clin Neurophar-macol 1998; 21(5):285–288
   Google Scholar
• Molho ES, Factor SA: Worsening of motor features of Parkinsonism with olanzapine. Mov Disord 1999; 14(6): 1014–1016
   PubMed Web of Science ®Google Scholar
• Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG: Olanzapine in dementia with Lewy bodies: A clinical study. Int J Geriatr Psychiatry 1999; 14(6): 459–466
   Google Scholar
• Sipahimalani A, Masand PS: Olanzapine in the treatment of delirium. Psychosomatics 1998; 39:422–430
   PubMed Web of Science ®Google Scholar
• Passik SD, Cooper M: Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage 1999; 17:219–223
   Google Scholar
• Almeida OP: Olanzapine for the treatment of tardive dyski-nesia [letter]. J Clin Psychiatry 1998; 59:380–381
   PubMed Web of Science ®Google Scholar
• Littrell KH, Johnson CG, Littrell S, Peabody CD: Marked re-duction of tardive dyskinesia with olanzapine. Arch Gen Psy-chiatry 1998; 55:279–280
   PubMed Web of Science ®Google Scholar
• O'Brien J, Barber R: Marked improvement in tardive dyskine-sia following treatment with olanzapine in an elderly subject [letter]. Bri J Psychiatry 1998; 172:186
   PubMed Web of Science ®Google Scholar
• Jaffe ME, Simpson GM: Reduction of tardive dystonia with olanzapine [letter]. Am J Psychiatry 1999; 156(12):2016
   Google Scholar
• Pfizer Study 054. Pfizer, Inc. Report of Ziprasidone Clinical Pharmacology Protocol. Rockville, MD: FDA Center for Drug Evaluation and Research Division of Cardiorenal Drug Prod-ucts Consultation; June 14,2000
   Google Scholar
• Dunayevich E, Strakowski SM: Olanzapine-induced tardive dystonia [letter]. Am J Psychiatry 1999; 156(10):1662
   Web of Science ®Google Scholar
• Ananth J, Kenan J: Tardive dyskinesia associated with olan-zapine monotherapy [letter]. J Clin Psychiatry 1999; 60(12): 870
   Google Scholar
• Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative inci-dence of treatment-emergent tardive dyskinesia with olanza-pine or haloperidol. Am J Psychiatry 1997; 154(9):1248–1254
   PubMed Web of Science ®Google Scholar
• Johnson V, Bruxner G: Neuroleptic malignant syndrome asso-ciated with olanzapine. Austr N ZJ Psychiatry 1998; 32(6):884–886
   PubMed Web of Science ®Google Scholar
• Gheorghiu S, Knobler HY, Drumer D: Recurrence of neu-roleptic malignant syndrome with olanzapine treatment. Am J Psychiatry 1999; 156(11):1836
   Google Scholar
• Aubry J-M, Simon AE, Bertschy G: Possible induction of ma-nia and hypomania by olanzapine or risperidone: A critical review of reported cases. J Clin Psychiatry 2000; 61(9):649–655
   Google Scholar
• Benazzi F, Rossi E: Mania induced by olanzapine. Hum Psy-chopharmacol Clin Exp 1998; 13:585–586
   Google Scholar
• Bryden KE, Kopala LC: Body Mass Index increase of 58% associated with olanzapine [letter]. Am J Psychiatry 1999; 156(11):1835
   Google Scholar
• Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60(11):767–770
   Google Scholar
• Melkersson KI, Hulting A-L, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated pa-tients with schizophrenia or related psychoses. J Clin Psychia-try 2000; 61(10):742–749
   Google Scholar
• Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B: Olanzapine-induced weight gain. Ann Clin Psychiatry 1998; 10(1):39
   Google Scholar
• Solomon CG, Manson JE: Obesity and mortality: A review of the epidemiologic data. Am J Clin Nutr 1997; 66\(Suppl 4): 1044S–1050S
   Google Scholar
• Ober SK, Hudak R, Rusterholtz A: Hyperglycaemia and olan-zapine [letter]. Am J Psychiatry 1999; 156(6):970
   Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SM, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778–783
   PubMed Web of Science ®Google Scholar
• Dernovsek MK, Tavcar R: Olanzapine appears haematolog-ically safe in patients who developed blood dyscrasia on clozapine and risperidone. Int Clin Psychopharmacol 2000; 15(4):237–238
   Google Scholar
• Steinwachs A, Grohmann R, Pedrosa F, Ruther E, Schwerdt-ner I: Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry 1999; 32(4):154–156
   Google Scholar
• Flynn SW, Altman S, MacEwan GW, Black LL, Greenidge LL, Honer WG: Prolongation of clozapine-induced granulocy-topenia associated with olanzapine [letter]. J Clin Psychophar-macol 1997; 17:494–495
   PubMedGoogle Scholar
• Doucette DE, Grenier JP, Robertson PS: Olanzapine-induced acute pan creatitis. Ann Pharmacother 2000; 34(10):1128–1131
   Google Scholar
• Compton MT, Saldivia A, Berry SA: Recurrent priapism dur-ing treatment with clozapine and olanzapine [letter]. Am J Psychiatry 2000; 157(4):659
   Google Scholar
• Heckers S, Anick D, Boverman JF, Stern TA: Priapism fol-lowing olanzapine administration in a patient with multiple sclerosis. Psychosomatics 1998; 39:288–290
   PubMed Web of Science ®Google Scholar
• Deirmenjian JM, Erhart SM, Wirshing DA, Spellberg BJ, Wirshing WC: Olanzapine-induced reversible priapism: A case report. J Clin Psychopharmacol 1998; 18:351–353
   PubMed Web of Science ®Google Scholar
• Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Breier A: A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Pa-per presented at the 14th annual meeting of the American Association for Geriatric Psychiatry; Feb. 23–26, 2001; San Francisco, CA
   Google Scholar